Navigation Links
Micromet to Present at The 8th Annual BIO Investor Forum Conference on October 29, 2009
Date:10/21/2009

tatements include statements regarding the efficacy, safety and intended utilization of blinatumomab and other product candidates, the conduct, timing and results of future clinical trials, and expectations of the future expansion of our product pipeline and collaborations. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. These factors and others are more fully discussed in Micromet's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2009, filed with the SEC on August 6, 2009, as well as other filings by the company with the SEC.

SOURCE Micromet, Inc.


'/>"/>
SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients
2. Micromet Presents Update on Blinatumomabs Response Rate and Duration in a Phase 1 Study in Non-Hodgkins Lymphoma Patients
3. Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day
4. Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells
5. Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203
6. Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients
7. Micromet Key Events for 2009
8. Micromet Expands Committed Equity Financing Facility to $75 Million
9. Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
10. Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy
11. Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... THOUSAND OAKS, Calif. , Oct. 17, 2014 /PRNewswire/ ... appointment of R. Sanders Williams , M.D., president ... L. Mahley Distinguished Professor.  "We are ... the Amgen Board," said Robert A. Bradway , ... deep and distinguished experience in academic medicine and his ...
(Date:10/17/2014)... , October 17, 2014 ... Markets ( http://www.researchandmarkets.com/research/rxznjk/micro_market ) has announced the ... : North American Automated External Defibrillators ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,The report North ... analyzes the market of devices based ...
(Date:10/17/2014)... 2014  UBM Medica US announces that Endocrinology ... other clinicians who treat patients with type 2 ... use of insulin .  Nearly all ... therapy – daily injections of one or more ... the function of pancreatic beta cells. Insulin is a ...
Breaking Medicine Technology:Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 2Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 3Micro Market Monitor : North American Automated External Defibrillators (AED) Market 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 3
... SUNNYVALE, Calif., Feb. 28, 2011 /PRNewswire/ ... company developing innovative technologies in diabetes management, announced that ... Silicon Valley Bank and ... used to help complete clinical trials and commercialize POGO™, ...
... Feb. 28, 2011 Advanced Cell Diagnostics, Inc. ... study utilizing RNAscope™ technology to detect human papillomavirus ... head and neck cancer. HPV status determined by ... patient outcome and highly concordant with that determined ...
Cached Medicine Technology:Intuity Medical Secures $20M Credit Facility From Silicon Valley Bank and Oxford Finance Corporation 2Intuity Medical Secures $20M Credit Facility From Silicon Valley Bank and Oxford Finance Corporation 3ACD Announces Clinical Study Results Using its RNAscope™ Technology 2ACD Announces Clinical Study Results Using its RNAscope™ Technology 3
(Date:10/20/2014)... (PRWEB) October 20, 2014 AttorneyOne.com, a recognized ... latest information from the FDA on Sit and Slim ... 10 not to purchase or use Sit and Slim II ... Slim II is promoted as weight loss product on various ... from the market in 2010 for safety reasons, can significantly ...
(Date:10/20/2014)... October 20, 2014 Based on ... the only imaging assays capable of determining DNA ... test.  With these three dimensions of high-resolution data, ... detect the widest range of disease-causing genetic rearrangements, ... by other genomic tools, including today’s advanced sequencing ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 It’s hard to ... many orphans and vulnerable children around the world, it’s a ... some people, many children are forced to walk barefoot on ... their families or play with their friends. , Buckner ... with Air1 Radio in October to encourage support ...
(Date:10/19/2014)... Hastings and Hastings, a Phoenix personal injury law ... greater Phoenix area and across Arizona reports record demand ... automobile accidents. Statistics have indicated a steady increase in ... such, Hastings and Hastings has seen a steady increase ... have been injured through no fault of their own ...
(Date:10/19/2014)... Dallas, Texas (PRWEB) October 20, 2014 ... therapeutic development for Partial Seizure, complete with comparative ... target, mechanism of action (MoA), route of administration ... and featured news and press releases. It also ... for Partial Seizure and special features on late-stage ...
Breaking Medicine News(10 mins):Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4
... , ST. LOUIS, Aug. 24 ... herbicide Atrazine have attorney and clean water advocate Steve Tillery ... and accountability for the herbicide,s manufacturers. , , ... the New York Times and the Peoria Journal Star have ...
... , , , OAKLAND, ... LATINA Style magazine on the publication,s list of the 50 ... , The LATINA Style survey, now in ... the value of diversity in the workplace, and identifies the corporations in ...
... Institute of Allergy and Infectious Diseases (NIAID), a component ... applications for a new initiative to establish a consortium ... these cooperative centerswhich together will receive funding up to ... immune system under normal conditions and to understand how ...
... - Concussions, whether from an accident, sporting event, or ... mental processes. Scientists have debated for centuries whether concussions ... changes that merely impair the way brain cells function, ... at Albert Einstein College of Medicine of Yeshiva University ...
... State University study shows that invigorated and dedicated employees ... home life. K-State psychology researchers studied how positive ... interactions. They found that employees who are engaged in ... dedication and absorption in daily activities, have better moods ...
... , SWARTZ CREEK, Mich., Aug. ... Health Services Division is partnering with CareSource in Ohio to ... outcomes and reduce healthcare costs associated with the disease. As ... is focused on the early identification and treatment of their ...
Cached Medicine News:Health News:Korein Tillery: Is Time Running Out for the Manufacturers of the Herbicide Atrazine? 2Health News:Korein Tillery: Is Time Running Out for the Manufacturers of the Herbicide Atrazine? 3Health News:Kaiser Permanente Named 2009 Company of the Year by LATINA Style Magazine 2Health News:Kaiser Permanente Named 2009 Company of the Year by LATINA Style Magazine 3Health News:NIAID to fund new human immune profiling research centers 2Health News:Strong link found between concussions and brain tissue injury 2Health News:Strong link found between concussions and brain tissue injury 3Health News:Researchers find that employees who are engaged in their work have happier home life 2Health News:Diplomat Specialty Pharmacy Partners With CareSource -- Launches Chronic Kidney Disease Management Program with Ohio Plan 2
... products are offered as 1-piece or modular, ... modular instruments may be customized with handles ... ratchets, insulation and flush ports. Many standard ... specifications may affect delivery times. , ...
... The Featured Products are ... Mediflex and are offered ... in regular or extra ... equipped with insulation, flush ...
... Products are kept in ... are offered as 1-piece ... or extra long lengths. ... insulation, flush ports, rotating ...
... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
Medicine Products: